- Home
- TOYO vs SKYE Comparison
TOYO vs SKYE Comparison
Compare TOYO & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOYO
- SKYE
- Stock Information
- Founded
- TOYO 2022
- SKYE 2012
- Country
- TOYO Japan
- SKYE United States
- Employees
- TOYO N/A
- SKYE N/A
- Industry
- TOYO
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- TOYO
- SKYE Health Care
- Exchange
- TOYO NYSE
- SKYE Nasdaq
- Market Cap
- TOYO 115.2M
- SKYE 108.3M
- IPO Year
- TOYO N/A
- SKYE N/A
- Fundamental
- Price
- TOYO $3.04
- SKYE $4.95
- Analyst Decision
- TOYO
- SKYE Buy
- Analyst Count
- TOYO 0
- SKYE 6
- Target Price
- TOYO N/A
- SKYE $18.67
- AVG Volume (30 Days)
- TOYO 23.4K
- SKYE 195.9K
- Earning Date
- TOYO 08-21-2024
- SKYE 11-07-2024
- Dividend Yield
- TOYO N/A
- SKYE N/A
- EPS Growth
- TOYO N/A
- SKYE N/A
- EPS
- TOYO 0.76
- SKYE N/A
- Revenue
- TOYO $200,455,385.00
- SKYE N/A
- Revenue This Year
- TOYO N/A
- SKYE N/A
- Revenue Next Year
- TOYO N/A
- SKYE N/A
- P/E Ratio
- TOYO $3.97
- SKYE N/A
- Revenue Growth
- TOYO N/A
- SKYE N/A
- 52 Week Low
- TOYO $1.36
- SKYE $1.44
- 52 Week High
- TOYO $15.61
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- TOYO N/A
- SKYE 47.26
- Support Level
- TOYO N/A
- SKYE $5.16
- Resistance Level
- TOYO N/A
- SKYE $5.67
- Average True Range (ATR)
- TOYO 0.00
- SKYE 0.51
- MACD
- TOYO 0.00
- SKYE -0.03
- Stochastic Oscillator
- TOYO 0.00
- SKYE 38.41
About TOYO TOYO CO LTD
Toyo Co Ltd along with its subsidiaries is engaged in research and development, production, and sales of solar cells.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.